Compare Biogen Inc (BIIB) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Workiva Inc — how do they compare? Biogen Inc trades at $207.22 (market cap $30.13B), while Workiva Inc trades at $67.72 (market cap $3.76B). The key difference: Biogen Inc is far larger — about 8× Workiva Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | WK | |
|---|---|---|
Market Cap | $30.13B | $3.76B |
Sector | Health | Technology |
52-Week High | $216.63 | $93.31 |
52-Week Low | $128.93 | $44.31 |
Enterprise Value | $37.20B | $3.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Workiva (WK) trades at $67.62, up 0.45% with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings performance with three consecutive quarterly beats and revenue growth accelerating to 19% in Q2 2026. Technical indicators signal bullish momentum despite overbought RSI conditions, while fundamentals reflect improving profitability with net income margin turning positive to 4.87% in 2026.
Outlook remains positive with 89% analyst buy ratings and $69 consensus target offering 2% upside. Key opportunities include AI product expansion and sustained subscription growth, while risks involve high valuation multiples (P/E 82.2) and competitive pressures in regulatory software. The stock's proximity to 52-week highs suggests momentum but warrants caution on pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
